These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9090787)

  • 21. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombopoietin-stimulated ex vivo expansion of human bone marrow megakaryocytes.
    Schattner M; Lefebvre P; Mingolelli SS; Goolsby CL; Rademaker A; White JG; Foster D; Green D; Cohen I
    Stem Cells; 1996 Mar; 14(2):207-14. PubMed ID: 8991540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro expansion of CD34+/CD41+ cells from human peripheral blood CD34+/CD41- cells: role of cytokines for in vitro proliferation and differentiation of megakaryocytic progenitors.
    Koizumi K; Sawada K; Yamaguchi M; Notoya A; Tarumi T; Takano H; Fukada Y; Nishio M; Katagiri E; Yasukouchi T; Sato N; Sekiguchi S; Koike T
    Exp Hematol; 1998 Nov; 26(12):1140-7. PubMed ID: 9808053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expansion of megakaryocyte progenitors from CD34+-enriched mobilized peripheral blood stem cells is inhibited by Flt3-L.
    Case J; Hicks C; Trickett A; Kwan YL; Manoharan A
    J Interferon Cytokine Res; 2006 Feb; 26(2):76-82. PubMed ID: 16487027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation.
    Avigan D; Wu Z; Gong J; Joyce R; Levine J; Elias A; Richardson P; Milano J; Kennedy L; Anderson K; Kufe D
    Clin Cancer Res; 1999 Oct; 5(10):2735-41. PubMed ID: 10537336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of cytokines for expansion of the megakaryocyte and granulocyte lineages.
    LaIuppa JA; Papoutsakis ET; Miller WM
    Stem Cells; 1997; 15(3):198-206. PubMed ID: 9170211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF).
    Smith SL; Bender JG; Berger C; Lee WJ; Loudovaris M; Martinson JA; Opotowsky JD; Qiao X; Schneidkraut M; Sweeney P; Unverzagt KL; Van Epps DE; Williams DE; Williams SF; Zimmerman TM
    J Hematother; 1997 Aug; 6(4):323-34. PubMed ID: 9377071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
    Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
    Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers.
    Schwartz GN; Kammula U; Warren MK; Park MK; Yan XY; Marincola FM; Gress RE
    Stem Cells; 2000; 18(5):331-42. PubMed ID: 11007917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions.
    Cardier JE; Erickson-Miller CL; Murphy MJ
    Stem Cells; 1997; 15(4):286-90. PubMed ID: 9253112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients.
    Gazitt Y; Liu Q
    Stem Cells; 2001; 19(1):37-45. PubMed ID: 11209089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of peripheral blood steady-state progenitor cells preserved in liquid culture conditions with or without GM-CSF and IL2.
    Sawadogo D; Martínez MJ; Merino J; Subirá ML; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(4):7-14. PubMed ID: 9499829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant.
    Maharaj D; Steinberg JP; Gouvea JV; Gieser PW
    Bone Marrow Transplant; 1999 Mar; 23(6):539-48. PubMed ID: 10217183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proliferative properties of human umbilical cord blood megakaryocyte progenitor cells to human thrombopoietin.
    Hagiwara T; Kodama I; Horie K; Kato T; Miyazaki H
    Exp Hematol; 1998 Mar; 26(3):228-35. PubMed ID: 9502619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
    Cesana C; Regazzi E; Garau D; Caramatti C; Mangoni L; Rizzoli V
    Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.